|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.
|
|
2
|
Chong CR and Sullivan DJ Jr: New uses for
old drugs. Nature. 448:645–646. 2007.
|
|
3
|
Al-Bari MA: Chloroquine analogues in drug
discovery: New directions of uses, mechanisms of actions and toxic
manifestations from malaria to multifarious diseases. J Antimicrob
Chemother. 70:1608–1621. 2015.
|
|
4
|
Hui B, Shi YH, Ding ZB, Zhou J, Gu CY,
Peng YF, Yang H, Liu WR, Shi GM and Fan J: Proteasome inhibitor
interacts synergistically with autophagy inhibitor to suppress
proliferation and induce apoptosis in hepatocellular carcinoma.
Cancer. 118:5560–5571. 2012.
|
|
5
|
Ding ZB, Hui B, Shi YH, Zhou J, Peng YF,
Gu CY, Yang H, Shi GM, Ke AW, Wang XY, et al: Autophagy activation
in hepatocellular carcinoma contributes to the tolerance of
oxaliplatin via reactive oxygen species modulation. Clin Cancer
Res. 17:6229–6238. 2011.
|
|
6
|
Du H, Yang W, Chen L, Shi M, Seewoo V,
Wang J, Lin A, Liu Z and Qiu W: Role of autophagy in resistance to
oxaliplatin in hepatocellular carcinoma cells. Oncol Rep.
27:143–150. 2012.
|
|
7
|
Gao L, Song JR, Zhang JW, Zhao X, Zhao QD,
Sun K, Deng WJ, Li R, Lv G, Cheng HY, et al: Chloroquine promotes
the anticancer effect of TACE in a rabbit VX2 liver tumor model.
Int J Biol Sci. 9:322–330. 2013.
|
|
8
|
Liang X, Tang J, Liang Y, Jin R and Cai X:
Suppression of autophagy by chloroquine sensitizes
5-fluorouracil-mediated cell death in gallbladder carcinoma cells.
Cell Biosci. 4:102014.
|
|
9
|
Ratikan JA, Sayre JW and Schaue D:
Chloroquine engages the immune system to eradicate irradiated
breast tumors in mice. Int J Radiat Oncol Biol Phys. 87:761–768.
2013.
|
|
10
|
Lakhter AJ, Sahu RP, Sun Y, Kaufmann WK,
Androphy EJ, Travers JB and Naidu SR: Chloroquine promotes
apoptosis in melanoma cells by inhibiting BH3 domain-mediated PuMA
degradation. J Invest Dermatol. 133:2247–2254. 2013.
|
|
11
|
Geng Y, Kohli L, Klocke BJ and Roth KA:
Chloroquine-induced autophagic vacuole accumulation and cell death
in glioma cells is p53 independent. Neuro Oncol. 12:473–481.
2010.
|
|
12
|
Fan C, Wang W, Zhao B, Zhang S and Miao J:
Chloroquine inhibits cell growth and induces cell death in A549
lung cancer cells. Bioorg Med Chem. 14:3218–3222. 2006.
|
|
13
|
Jiang PD, Zhao YL, Deng XQ, Mao YQ, Shi W,
Tang QQ, Li ZG, Zheng YZ, Yang SY and Wei YQ: Antitumor and
antimetastatic activities of chloroquine diphosphate in a murine
model of breast cancer. Biomed Pharmacother. 64:609–614. 2010.
|
|
14
|
Rahim R and Strobl JS: Hydroxychloroquine,
chloroquine, and all-trans retinoic acid regulate growth,
survival, and histone acetylation in breast cancer cells.
Anticancer Drugs. 20:736–745. 2009.
|
|
15
|
Chen P, Hu T, Liang Y, Jiang Y, Pan Y, Li
C, Zhang P, Wei D, Li P, Jeong LS, et al: Synergistic inhibition of
autophagy and neddylation pathways as a novel therapeutic approach
for targeting liver cancer. Oncotarget. 6:9002–9017. 2015.
|
|
16
|
Hoffman RM: The multiple uses of
fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer.
5:796–806. 2005.
|
|
17
|
Hoffman RM and Yang M: Whole-body imaging
with fluorescent proteins. Nat Protoc. 1:1429–1438. 2006.
|
|
18
|
Fischer TD, Wang JH, Vlada A, Kim JS and
Behrns KE: Role of autophagy in differential sensitivity of
hepatocarcinoma cells to sorafenib. World J Hepatol. 6:752–758.
2014.
|
|
19
|
Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke
AW, Wang XY, Dai Z, Peng YF, Gu CY, et al: Targeting autophagy
enhances sorafenib lethality for hepatocellular carcinoma via ER
stress-related apoptosis. Autophagy. 7:1159–1172. 2011.
|
|
20
|
Brito AF, Abrantes AM, Pinto-Costa C,
Gomes AR, Mamede AC, Casalta-Lopes J, Gonçalves AC,
Sarmento-Ribeiro AB, Tralhão JG and Botelho MF: Hepatocellular
carcinoma and chemotherapy: The role of p53. Chemotherapy.
58:381–386. 2012.
|
|
21
|
Müller M, Strand S, Hug H, Heinemann EM,
Walczak H, Hofmann WJ, Stremmel W, Krammer PH and Galle PR:
Drug-induced apoptosis in hepatoma cells is mediated by the CD95
(APo-1/Fas) receptor/ligand system and involves activation of
wild-type p53. J Clin Invest. 99:403–413. 1997.
|
|
22
|
Balic A, Sørensen MD, Trabulo SM, Sainz B
Jr, Cioffi M, Vieira CR, Miranda-Lorenzo I, Hidalgo M, Kleeff J,
Erkan M, et al: Chloroquine targets pancreatic cancer stem cells
via inhibition of CXCR4 and hedgehog signaling. Mol Cancer Ther.
13:1758–1771. 2014.
|
|
23
|
Zheng Y, Zhao YL, Deng X, Yang S, Mao Y,
Li Z, Jiang P, Zhao X and Wei Y: Chloroquine inhibits colon cancer
cell growth in vitro and tumor growth in vivo via induction of
apoptosis. Cancer Invest. 27:286–292. 2009.
|
|
24
|
Kim EL, Wüstenberg R, Rübsam A,
Schmitz-Salue C, Warnecke G, Bücker EM, Pettkus N, Speidel D, Rohde
V, Schulz-Schaeffer W, et al: Chloroquine activates the p53 pathway
and induces apoptosis in human glioma cells. Neuro oncol.
12:389–400. 2010.
|
|
25
|
Farombi EO: Genotoxicity of chloroquine in
rat liver cells: Protective role of free radical scavengers. Cell
Biol Toxicol. 22:159–167. 2006.
|
|
26
|
Krajewski WA: Alterations in the
internucleosomal DNA helical twist in chromatin of human
erythroleukemia cells in vivo influences the chromatin higher-order
folding. FEBS Lett. 361:149–152. 1995.
|
|
27
|
Akiyama T, Dass CR and Choong PF:
Bim-targeted cancer therapy: A link between drug action and
underlying molecular changes. Mol Cancer Ther. 8:3173–3180.
2009.
|
|
28
|
Gillings AS, Balmanno K, Wiggins CM,
Johnson M and Cook SJ: Apoptosis and autophagy: BIM as a mediator
of tumour cell death in response to oncogene-targeted therapeutics.
FEBS J. 276:6050–6062. 2009.
|
|
29
|
Wickenden JA, Jin H, Johnson M, Gillings
AS, Newson C, Austin M, Chell SD, Balmanno K, Pritchard CA and Cook
SJ: Colorectal cancer cells with the BRAFv600E mutation
are addicted to the ERK1/2 pathway for growth factor-independent
survival and repression of BIM. Oncogene. 27:7150–7161. 2008.
|
|
30
|
Cartlidge RA, Thomas GR, Cagnol S, Jong
KA, Molton SA, Finch AJ and McMahon M: Oncogenic
BRAFv600E inhibits BIM expression to promote melanoma
cell survival. Pigment Cell Melanoma Res. 21:534–544. 2008.
|
|
31
|
Cragg MS, Kuroda J, Puthalakath H, Huang
DC and Strasser A: Gefitinib-induced killing of NSCLC cell lines
expressing mutant EGFR requires BIM and can be enhanced by
BH3 mimetics. PLoS Med. 4:1681–1690. 2007.
|
